Invitrocue Limited is an innovative life sciences company that specialises in developing in vitro and in vivo models that improve the efficacy and safety evaluation of new drugs for biotechnology, pharmaceutical, and consumer healthcare companies.
Headquartered in Singapore and with operations in Australia, China, Hong Kong and Germany, Invitrocue’s Onco-PDO™ technology enables patient-derived cancer cells (organoids) to be cultured in laboratories for testing against a panel of drugs to support personalised clinical decisions.
Our expertise in developing predictive preclinical models can help to reduce the time and cost of product development and minimize the risks of downstream testing.
By enabling assessments of the best ways for drugs to be developed, Invitrocue creates better, faster and more affordable disease treatments, that work towards the company’s goal of creating a healthier society by providing patients with the best possible care.
To learn more please visit: https://www.invitrocue.com
Company Details
- Founded
- 2019
- Address
- 11w Science Park Avenue West, Biotech Center 2,hong Kong
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.invitrocue.com/
- Keywords
- Boston.
- HQ
- Shatin, HK Science Park
Invitrocue Hong Kong Questions
Invitrocue Hong Kong's website is https://www.invitrocue.com/
Invitrocue Hong Kong's LinkedIn profile is https://hk.linkedin.com/company/invitrocue-hk
Invitrocue Hong Kong's industry is
Biotechnology Research
Invitrocue Hong Kong's top competitors are
Invitrocue Brasil,
Invitrocue (Hk) Limited,
Invitro Prime,
Innodetection Limited,
Cordlife (Hong Kong) Limited,
Istudy Learning Center,
Vista Health Pte Ltd,
Harmony Baby Nutrition,
Invitrocue,
Bleeding Fingers Music.
Invitrocue Hong Kong's categories are Biotechnology Research
Invitrocue Hong Kong's founding year is 2019
